Table 1. Association of HEY2 expression and clinical features of patients with HCC in training cohort (n=351).
Variable | Hey2 expression | |||
---|---|---|---|---|
All cases | Low expression | High expression | P valuea | |
Age (years) b | 0.811 | |||
≤ 47 | 156 | 74 (47.4%) | 82 (52.6%) | |
> 47 | 195 | 90 (46.2%) | 105 (53.8%) | |
Gender | 0.004 | |||
Male | 315 | 139 (44.1%) | 176 (55.9%) | |
Female | 36 | 25 (69.4%) | 11 (30.6%) | |
HBsAg | 0.712 | |||
Negative | 53 | 26 (49.1%) | 27 (50.9%) | |
Positive | 298 | 138 (46.3%) | 160 (53.7%) | |
AFP (ng/ml) | 0.728 | |||
≤ 20 | 89 | 43 (48.3%) | 46 (51.7%) | |
> 20 | 262 | 121 (46.2%) | 141 (53.8%) | |
Cirrhosis | 0.303 | |||
Yes | 301 | 144 (47.8%) | 157 (52.2%) | |
No | 50 | 20 (40.0%) | 30 (60.0%) | |
Tumor size (cm) | 0.740 | |||
≤ 5 | 82 | 37 (45.1%) | 45 (54.9%) | |
> 5 | 269 | 127 (47.2%) | 142 (52.8%) | |
Tumor multiplicity | 0.017 | |||
Single | 221 | 114 (51.6%) | 107 (48.4%) | |
Multiple | 130 | 50 (38.5%) | 80 (61.5%) | |
Differentiation | 0.019 | |||
Well | 20 | 10 (50.0%) | 10 (50.0%) | |
Moderate | 167 | 90 (53.9%) | 77 (46.2%) | |
Poor | 160 | 64 (40.0%) | 96 (60.0%) | |
Undifferentiated | 4 | 0 (0%) | 4 (100%) | |
Stage | 0.006 | |||
I | 119 | 69 (58.0%) | 50 (42.0%) | |
II | 69 | 26 (37.7%) | 43 (62.3%) | |
III | 120 | 46 (38.3%) | 74 (61.7%) | |
IV | 43 | 23 (53.5%) | 20 (46.5%) | |
Tumor capsule | 0.811 | |||
Incomplete | 195 | 90 (46.2%) | 105 (53.8%) | |
Complete | 156 | 74 (47.4%) | 82 (52.6%) | |
LNM | 0.952 | |||
Yes | 26 | 12 (46.2%) | 14 (53.8%) | |
No | 325 | 152 (46.8%) | 173 (53.2%) | |
Vascular invasion | 0.097 | |||
Yes | 78 | 30 (38.5%) | 48 (61.5%) | |
No | 273 | 134 (49.1%) | 139 (50.9%) |
Chi-square test;
Median age; AFP, alpha-fetoprotein; HBsAg, hepatitis B surface antigen; LNM, lymph node metastasis.